Mammalian growth factor
A truncated mammalian growth factor, displaying homology to both basic and acidic fibroblast growth factor in a single polypeptide, is disclosed herein. The growth factor is substantially smaller (i.e. has fewer amino acid residues) than the full-length mammalian growth factor, has a higher affinity for fibroblast growth factor receptors than full-length K-FGF and basic fibroblast growth factor and increased mitogenic activity. Also disclosed herein are DNA sequences encoding the truncated growth factor, pharmaceutical formulations containing the truncated growth factor and methods to heal burns and wounds in a mammal by administering the pharmaceutical formulations.
Latest New York University Patents:
- Mechanical force redistribution sensor array embedded in a single support layer
- THERAPEUTIC STRATEGIES TO TARGET TUMORS WITH ALTERATIONS IN LKB1 PATHWAY
- Colloidal fingerprints for soft materials using total holographic characterization
- METHODS AND COMPOSITIONS FOR TREATING 4- HYDROXYPHENYLPYRUVATE DIOXYGENASE-LIKE (HPDL)-RELATED DISEASES OR DISORDERS
- Antibody-based molecules specific for the truncated ASP421 epitope of Tau and their uses in the diagnosis and treatment of tauopathy
Claims
1. A polypeptide having the amino acid sequence as set forth in SEQ. ID NO: 1.
2. A pharmaceutical formulation for treating a mammal suffering from wounds or burns comprising a truncated K-FGF protein having a molecular weight of about 14,000 daltons and an average FGF receptor binding affinity of about 9.5.times.10.sup.-11 M and a pharmaceutically acceptable carrier or diluent.
3. The pharmaceutical formulation of claim 2 comprising a topical pharmaceutical formulation.
4. The pharmaceutical formulation of claim 2 wherein said protein has about 4 to 5 times greater mitogenic activity than full-length K-FGF when assayed in, the BALB/c-3T3 mitogenic assay.
5. A truncated K-FGF protein having a molecular weight of 14,000 Daltons, and an average FGF receptor binding affinity of about 9.5.times.10.sup.-11 M.
6. The truncated protein of claim 5 wherein said protein has about 4 to 5 times greater mitogenic activity than full-length K-FGF when assayed in the BALB/c-3T3 mitogenic assay.
7. A pharmaceutical formulation for treating a mammal suffering from wounds or burns comprising a polypeptide having the amino acid sequence as set forth in SEQ. ID NO: 1 and a pharmaceutically acceptable carrier or diluent.
8. The pharmaceutical formulation of claim 7 comprising a topical pharmaceutical formulation.
4444760 | April 24, 1984 | Thomas |
4716102 | December 29, 1987 | Levy |
5106731 | April 21, 1992 | Salhudden et al. |
5126323 | June 30, 1992 | Rogers et al. |
5352589 | October 4, 1994 | Bergonzoni et al. |
5387673 | February 7, 1995 | Seddon et al. |
WO 8607595 | December 1986 | WOX |
- Moscatelli et al., Fed. Proc., 45:6, 1382, 1986. Abraham et al., Science, 233:545-548, 1986. Gimenez-Gallego et al., Biochem. Biophys. Res. Comm., 135:611-617, 1986. Sakamoto et al., Proc. Natl. Acad. Sci., 83:3997-4001, 1986. Taira et al., Proc. Natl. Acad. Sci., 84:2980-2984, 1987. Rueger et al., Antibiot. Chemother. (Basel), 32:43-7, 1984 (abstract only). Boldogh et al., Int. J. Cancer, 28:469-474, 1981 (abstract only). Abraham et al., EMBO J., 5:10, 2523-2528, 1986. Esch et al., Proc. Natl. Acad. Sci., 82:6507-6511, 1985. Delli-Bovi et al., Cell, 50:729-735, 1987. Delli-Bovi et al., Proc.Natl. Acad. Sci., 84:5660-5664, 1987. Delli-Bovi et al., Mol. and Cell. Bio., 8:2933-2941, 1988. Huebner et al., Onc. Res., 3:263-270, 1988. Quarto et al., Onc. Res., 5:101-110, 1989. Velcich et al., Onc. Res., 5:31-37, 1989. Basilico et al., Annals of N.Y. Acad. Sci., 567:95-103, 1989. Kaner et al., Science, 248:1410-1413, 1990. Mansukhani et al., Proc. Natl. Acad. Sci., 87:4222-4225, 1990. Talarico et al., Proc. Natl. Acad. Sci., 87:4222-4225, 1990. Curatola et al., Mol. and Cell. Bio., 10:2475-2484, 1990. Talarico et al., Mol. and Cell. Bio., 11:1138-1145, 1991. Mansukhani et al., Proc. Natl. Acad. Sci., 89:3305-3309, 1992. Bernstein, S.C. et al., PNAS 82: 1726-1730, 1980.5. Lo, S.C., et al., AJP 118:7-13, 1985. Diamond, A. et al., Nature 305: 112-116, Sep., 1983. Diamond, A. et al., Science 225:516-519, Aug., 1984. Garrity, R.R. et al., Gene 68:63-72. Lerman, M.I. et al., Int J. Cancer 37: 293-302, 1986. Colburn, N.H. et al., Mol. & Cell. Biol 3:1182-1186, 1983. Colburn, N.H. et al., Cancer Research 48:1195-1200, 1988. 181162w, Chem. Abs. 108, 1986. 164592z, Chem. Abs. 101, 1984. 4527g, Chem. Abs. 96, 1982. 147328h, Chem. Abs. 105, 1986. Gallego et al., Biochem & Biophys. 135:2, 541-548, 1986. Weiss et al., Clin. Res., 34:2, 537A, 1986. 165184n, Chem Abs. 105, 1986. 192304z, Chem Abs. 107, 1987. Abraham et al., Science, 223:545-548, Aug., 1986.
Type: Grant
Filed: Jun 7, 1995
Date of Patent: Mar 16, 1999
Assignee: New York University (New York, NY)
Inventors: Claudio Basilico (New York, NY), Daniela Talarico (New York, NY)
Primary Examiner: Marianne P. Allen
Law Firm: Darby & Darby
Application Number: 8/478,485
International Classification: C07K 14475; C07K 1450; A61K 3818;